| Methods |
Randomized |
| Participants |
Adults (mean age: 70)
Hospitalized
CAP |
| Interventions |
Atypical: IV clarythromycin 500 mg X 2/d 3 to 5/d , followed by PO clarythromycin 500 mg X 2/d
Non‐atypical: IV amoxicillin‐clavulanate 1.2 G X 4/d 3‐5/d, followed by PO amoxicillin‐clavulanate 625 mg X 3/d |
| Outcomes |
Failure = change of ABX, persistence or progression of sx/radiological finding, death, s/e enabling completion of trial |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Low risk |
Randomization was performed using sealed envelopes with random numbers |
| Allocation concealment (selection bias) |
Low risk |
Sealed opaque envelopes with numbers |
| Incomplete outcome data (attrition bias)
Mortality |
High risk |
112/127 patients evaluated |
| Incomplete outcome data (attrition bias)
Failure |
Unclear risk |
112/127 patients evaluated |
| Selective reporting (reporting bias) |
Low risk |
Not identified |
| Other bias |
Unclear risk |
Sponsored |
| Blinding of participants and personnel (performance bias)
All outcomes |
High risk |
None |
| Blinding of outcome assessment (detection bias)
All outcomes |
High risk |
None |
